These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
    Author: Watanabe Y, Iwa T.
    Journal: J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412.
    Abstract:
    A streptococcal preparation, OK-432, was employed as the adjuvant immunotherapeutic agent combined with chemotherapy in cases of lung cancer. To evaluate the clinical efficacy of OK-432, patients admitted between 1975 and 1982 were randomized into two groups: an immunochemotherapy, or immunotherapy, group and a chemotherapy, or control, group. For each case, a fixed protocol of chemotherapy was administered using a combination of three drugs. In this study, cases with small cell lung cancer were excluded, and the survival rates of cases with non-small cell lung cancer were evaluated. One hundred fifty-nine cases in the immunotherapy group and 152 cases in the control group were eligible for evaluation of long-term survival rates. When comparing the prognosis of the two groups, statistically significant improvements of the survival rate in the immunotherapy group were noted in the following categories: all cases, resected cases, nonresected cases, resected stage I + II cases, resected stage III + IV cases, completely resected cases, incompletely resected cases, and cases with epidermoid carcinoma. From the results of the present study, it is concluded that OK-432 is a potent immunopotentiative agent in the treatment of lung cancer.
    [Abstract] [Full Text] [Related] [New Search]